- Test Drive: Inside GM's All-New 2016 Chevy Volt Electric Hybrid
- Obamacare Actually Isn't All That Affordable -- Unless You're Broke
- What We Learned from Ordering a McDonald’s Egg McMuffin at 8 P.M.
- Fired for Farting and 3 Other Terminations That Don't Pass the Smell Test
- GM's New Diesel Engine Enters the Fray Amid Broad Public Censure for VW
Sarepta Therapeutics (SRPT) shares are declining after the company priced its secondary offering of 3.25 million shares at $39 per share.
An independent panel of health care experts did not include Exact Sciences' Cologuard on a draft list of recommended colon cancer screening tests in the U.S.
Apple (AAPL) shares bucked the upward trend in tech stocks after Citigroup analysts cut iPhone sales estimates on Monday.
Cannabis companies that run into serious financial trouble are caught between a rock and a hard place--namely, between clashing state and federal laws.
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
Jim Cramer said he's 'thrilled' about Twitter's (TWTR) appointment of Jack Dorsey and CEO, saying he can end the turmoil at the micro-blogging site.
Federal law prevents cannabis businesses from reorganizing in court, but for the first time the debate has gotten to a high judicial level.
2015 is shaping up to be the strongest period for mergers and acquisitions in the U.S. in at least 35 years, according to data from Thomson Reuters Deals Intelligence.
Cancer treatment company NovoCure (NVCR) debuted as a public company trading on the Nasdaq on Friday, despite weakness seen in the IPO market so far this year.
Xenoport (XNPT) shares are up nearly 20% after the company detailed its business restructuring plan.
Amicus Therapeutics (FOLD) shares are down over 30% after the FDA asked for more data on its Fabry disease treatment candidate.
U.S. stocks opened lower Friday as the Labor Department stunned Wall Street with a majorly disappointing September jobs report.
The S&P 500 fell almost 7% in the third quarter, the worst showing in four years.
Sarepta Therapeutics (SRPT) shares are up over 15% on new phase 2 trial data of its muscular dystrophy treatment candidate eteplirsen.
San Rafael, Calif.-based BioMarin says the deal will lift revenue from the PKU metabolic disorder treatment by up to $80 million in 2016.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas